KRRO-110 Receives Orphan Drug Designation from U.S. FDA for …
3 days ago · KRRO-110 is the first RNA editing development candidate from Korro’s proprietary OPERA TM platform and is currently being evaluated in the Phase 1/2a REWRITE clinical study for AATD. Dosing of ...
KRRO-110 (KRRO-110) - 药物靶点：ADAR_在研适应症：α1-抗胰 …
KRRO-110 is designed to co-opt an endogenous enzyme, Adenosine Deaminase Acting on RNA (ADAR), to edit the “A” variant on SERPINA1 RNA, repair an amino acid codon, and restore secretion of normal AAT protein.
Korro Bio, Inc. Announces FDA Orphan Drug Designation for KRRO-110 …
2 days ago · KRRO-110, a potential best-in-class compound based on preclinical data, is designed to co-opt an endogenous enzyme, Adenosine Deaminase Acting on RNA (ADAR), to edit the “A” variant on ...
Korro Bio's KRRO-110 Receives Orphan Drug Designation From …
2 days ago · KRRO-110 is the first RNA editing development candidate from Korro's OPERATM platform, with the potential to offer a differentiated treatment for AATD patients.
KRRO-110 在 AATD 和 Alpha-1 抗胰蛋白酶缺乏症-临床试验注册 …
Nov 4, 2024 · KRRO-110 是一种封装在脂质纳米颗粒 (LNP) 中的 RNA 编辑寡核苷酸，通过静脉 (IV) 输注作为 A 部分 (SAD) 中的单剂量、B 部分 (MAD) 中的多剂量进行给药。 研究衡量的是什么？ KRRO-110 的 PD 概况基于所有测量时间点 α-抗胰蛋白酶 (AAT) 酶水平相对于基线的变化（仅限 PiZZ 参与者）。 KRRO-110 半衰期 (t1/2) 的 PK 曲线、浓度-时间曲线下面积 (AUC) 和谷水平（仅限 MAD 队列）。 在这里您可以找到参与这项研究的人员和组织。 这些日期跟踪向 …
Pipeline - Korro Bio
KRRO-110 is a proprietary RNA editing oligonucleotide that is delivered to liver cells using a validated lipid nanoparticle (LNP) delivery system. Once inside these cells, KRRO-110 harnesses the naturally occurring ADAR editing system to repair the mutation that causes AATD and restore normal levels of AAT protein.
罕见病信息网 - raredisease.cn
Dec 10, 2023 · KRRO-110是一款专有的RNA编辑寡核苷酸药物，通过从Genevant公司授权的临床验证的脂质纳米颗粒（LNP）技术运送至肝细胞。 KRRO-110的设计旨在选择作用于RNA的内源酶腺苷脱氨酶(ADAR) ，修复RNA上的病理性单核苷酸变异（SNV），恢复正常的A1AT蛋白的生产。
A Phase 1/2a, Single- and Multiple-dose Escalation Study of KRRO-110
KRRO-110 is an RNA editing oligonucleotide encapsulated in a lipid nanoparticle (LNP) administered by intravenous (IV) infusion as a single dose in Part A (SAD), multi-dose in Part B (MAD).
Korro secures approvals to commence AATD trial of KRRO-110
Nov 22, 2024 · Korro Bio has secured approvals in Australia to commence the two-part Phase I/IIa REWRITE trial of its investigational product, KRRO-110, aimed at treating alpha-1 antitrypsin deficiency (AATD). The approvals were granted by the Australian Bellberry Human Research Ethics Committee (HREC) and the Therapeutic Goods Administration (TGA).
New Study to Assess Safety and Tolerability of KRRO-110 in AATD
Nov 21, 2024 · KRRO-110 is an RNA editing oligonucleotide compound designed to repair the gene and restore normal AAT production. The REWRITE study, sponsored by Korro Bio, Inc., will be a two-part single and multiple dose escalating trial that will enroll up to 64 adult participants with AATD who have the PiZZ genotype.
- Some results have been removed